Corcept Therapeutics (NASDAQ:CORT) Hits New 52-Week High – Still a Buy?

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) hit a new 52-week high during trading on Friday . The company traded as high as $122.88 and last traded at $122.62, with a volume of 19267 shares. The stock had previously closed at $121.05.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple EPS estimates. Forecasts increased for FY2026 to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also lifted, including Q1 2027 from a $0.17 loss to $0.11 profit and Q2 2028 from $0.69 to $1.17. These revisions suggest improving expectations for Corcept’s earnings trajectory, although Zacks continues to rate the shares “Hold.”
• Positive Sentiment: Recent operating results and growth commentary remain supportive. Corcept’s latest quarterly report showed EPS of $0.36 versus the $0.02 consensus estimate, while revenue rose 31.7% year over year to $256.15 million. An optimistic research article cited strong potential from Lifyorli’s launch in platinum-resistant ovarian cancer and continued Korlym growth, projecting revenue growth above 44% and substantial margin expansion. Like The Knicks, Corcept Rebounded And Is Crushing It
• Positive Sentiment: Wall Street price targets remain above the current trading level. Recent coverage includes Buy or equivalent ratings from Truist, Piper Sandler, HC Wainwright and Canaccord Genuity, with targets ranging from $150 to $165. The reported consensus target is $138.17, supporting the bullish momentum.
• Neutral Sentiment: Valuation is a risk consideration. Corcept’s market capitalization is approximately $13.1 billion and its P/E ratio is about 288, meaning investors are already paying a substantial premium for expected future growth. The shares are also near their 52-week high, which could increase sensitivity to disappointing results.
• Negative Sentiment: A director sold a sizable stake. Director David Mahoney sold 103,606 shares for approximately $12.25 million, reducing his ownership by 8.37%. He still owns more than 1.13 million shares, but the transaction may weigh on sentiment by signaling some profit-taking at elevated prices. Insider Selling: Corcept Therapeutics Director Sells Stock

Analyst Ratings Changes

CORT has been the subject of several recent analyst reports. UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday, May 28th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target for the company. in a report on Monday, July 27th. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Piper Sandler restated an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Finally, HC Wainwright lifted their price objective on Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $138.17.

Corcept Therapeutics Stock Performance

The company’s fifty day simple moving average is $96.60 and its two-hundred day simple moving average is $64.19. The company has a market capitalization of $13.30 billion, a price-to-earnings ratio of 293.05 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. During the same quarter in the prior year, the business posted $0.29 EPS. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. Sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.61 EPS for the current year.

Insider Activity

In other Corcept Therapeutics news, Director James N. Wilson sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $111.43, for a total transaction of $1,114,300.00. Following the sale, the director owned 1,074,543 shares in the company, valued at $119,736,326.49. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David L. Mahoney sold 103,606 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $118.25, for a total value of $12,251,409.50. Following the transaction, the director directly owned 1,133,539 shares in the company, valued at approximately $134,040,986.75. This represents a 8.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 520,146 shares of company stock valued at $48,903,764 over the last three months. Company insiders own 20.70% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CORT. Pathstone Holdings LLC grew its stake in Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after buying an additional 144 shares during the last quarter. State of Wyoming boosted its holdings in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 186 shares during the period. Gould Capital LLC boosted its holdings in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares during the period. Sequoia Financial Advisors LLC grew its position in shares of Corcept Therapeutics by 3.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 247 shares during the last quarter. Finally, Evergreen Capital Management LLC increased its stake in shares of Corcept Therapeutics by 3.0% in the fourth quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 248 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.